# Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

> **NCT05035147** · PHASE4 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 934 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** albumin-bound paclitaxel

## Key facts

- **NCT ID:** NCT05035147
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-25
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 934 (ESTIMATED)
- **Last updated:** 2021-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035147, "Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05035147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*